TriVascular boosted by $60m financing round
This article was originally published in Clinica
Executive Summary
Endovascular graft firm TriVascular has secured $60m in funding, which it will use to commercialise its Ovation abdominal stent graft system in Europe. The company closed a series C financing round, which was led by new investor Pinnacle Ventures. Existing investors New Enterprise Associates, Delphi Ventures, MPM Capital and Kearny Venture Partners also contributed. TriVascular (Santa Rosa, California) will use proceeds from the financing to launch Ovation in Europe, drive clinical research activity across three continents and fund next-generation product development. The Ovation system is designed to treat abdominal aortic aneurysm (AAAs), which affects nearly two million people in the US, according to TriVascular.
You may also be interested in...
Alere aided by professional diagnostics sales in fourth quarter
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra and Stout to work on expandable interbody device
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals